Psoriasis trials in Spain

In Spain 18 Also abroad 274

18 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)
Where
Barcelona, Bilbao, Ciudad Real, Córdoba, Elche, Las Palmas De Gran Canaria, Madrid, Murcia, Orihuela, Palma, San Cristóbal de La Laguna, Santander, Sant Joan d'Alacant, Torrelavega, Vitoria, Hospital laredo
Age
50 years and over
People
1,944
Run by
Instituto de Investigación Marqués de Valdecilla
See details and how to joinNCT07611747 · EU 2025-521086-28-00
Phase 4Taking people
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
Where
Bilbao, Madrid, Sabadell, Santiago de Compostela, Sevilla, Valencia
People
339 worldwide
Run by
Novartis Pharma AG
See details and how to joinNCT04638647 · EU 2023-504417-67-00
No phaseTaking people
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Where
Badalona, Barcelona, Madrid, Málaga, San Cristóbal de La Laguna, Valencia, Zaragoza
Age
18 years to 100 years
People
150
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07683065
Phase 3Taking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Santiago de Compostela, Valencia
Age
3 years to 64 years
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
Phase 3Taking people
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Where
Badalona, Barcelona, Las Palmas De Gran Canaria, Madrid, Malaga, Salamanca, Sevilla
Age
40 years and over
People
3,040 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07116967 · EU 2023-503766-24-00
Phase 3Taking people
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Where
Barcelona, Madrid, Santiago de Compostela- A Coruna
Age
12 years to 17 years
People
366 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06979453 · EU 2023-506296-97-00
Phase 3Taking people
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
Where
Alicante, Barakaldo, Esplugues De Llobregat, Las Palmas de Gran Canaria, Madrid
Age
4 years to 18 years
People
153 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04772079 · EU 2022-502519-13-00
Phase 2Taking people
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Where
Badalona, Barcelona, Madrid
Age
18 years and over
People
240 worldwide
Run by
Oruka Therapeutics, Inc.
See details and how to joinNCT07449702 · EU 2026-526898-42-00
Phase 3Taking people
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Where
Badajoz, Málaga, Sabadell, Santiago de Compostela, Sevilla, Valencia
Age
18 years and over
People
1,088 worldwide
Run by
Takeda
See details and how to joinNCT06671483 · EU 2024-513111-27-00
No phaseTaking people
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Where
Cartagena, El Palmar, León, Málaga, Murcia, Pontevedra, Toledo
Age
18 years and over
People
700 worldwide
Run by
AbbVie
See details and how to joinNCT07039110
No phaseNot yet taking people in Spain
Ceramol PSOR Cream as an Adjuvant Treatment in Patients With Mild-to-Moderate Psoriasis Treated With Narrowband UVB Phototherapy (CERAMOL PSOR CREMA)
Where
Madrid
Age
18 years and over
People
128
Run by
Unifarco SpA
See details and how to joinNCT07849101
Phase 1Taking people
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Where
Barcelona
Age
18 years and over
People
20 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06888193 · EU 2024-518689-29-00
Phase 3Taking people
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
Where
Alicante, Barcelona, Madrid, Santiago de Compostela
Age
4 years to 17 years
People
110 worldwide
Run by
Takeda
See details and how to joinNCT07250802 · EU 2025-522567-15-00
Phase 3Taking people
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Where
Alcobendas, Badajoz, Madrid, Málaga, Sabadell, San Cristóbal de La Laguna, Santander, Santiago de Compostela, Sevilla, Valencia, Vitoria
Age
18 years and over
People
1,182 worldwide
Run by
Takeda
See details and how to joinNCT07286058 · EU 2025-522586-30-00
Phase 3Taking people
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Where
Esplugues De Llobregat, Valencia
Age
5 years to 17 years
People
40 worldwide
Run by
AbbVie
See details and how to joinNCT06100744 · EU 2023-506026-36-00
Phase 3Taking people
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Where
Alicante, Barakaldo, Barcelona, Granada, L'hospitalet De Llobregat, Madrid, Valencia
Age
18 years and over
People
320 worldwide
Run by
Janssen - Cilag International
See details and how to join2023-505121-14-00 · EU 2023-505121-14-00
Phase 3Taking people
A Phase 3 Mechanistic Longitudinal Study to Evaluate the Impact of EARLY Risankizumab Treatment on TRM Cell Levels in Moderate-to-Severe Psoriasis
Where
Madrid
Age
18 years and over
People
30
Run by
Icr Medical S.L.
See details and how to join2025-521424-30-00 · EU 2025-521424-30-00
No phaseTaking people
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
Where
Granada, Huelva, Lorca, Madrid, Málaga, Murcia, Seville, Vigo
Age
18 years to 75 years
People
1,200 worldwide
Run by
AbbVie
See details and how to joinNCT06764693